| Literature DB >> 21336679 |
Bilgé Pakiz1, Shirley W Flatt, Wayne A Bardwell, Cheryl L Rock, Paul J Mills.
Abstract
BACKGROUND: Obesity is characterized by chronic mild inflammation and may influence the risk and progression of cancer.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21336679 PMCID: PMC3212681 DOI: 10.1007/s12529-010-9079-8
Source DB: PubMed Journal: Int J Behav Med ISSN: 1070-5503
Fig. 1CONSORT Chart for Healthy Weight Management Study including recruitment information
Fig. 2Weight loss intervention curriculum topics
Characteristics of the study groups at baseline
| Intervention | Control | |
|---|---|---|
| ( | ( | |
| Variables | Mean (SD) | Mean (SD) |
| Age, years | 56 (9) | 56 (8) |
| Years of education, years | 16 (2) | 16 (2) |
| Body mass index, kg/m2 | 30.8 (3.8) | 31.3 (5.2) |
| Weight, kg | 83.9 (11.8) | 87.2 (14.7) |
| Waist circumference, cm | 101.5 (12.0) | 106.7 (13.4) |
| Total body fat, kg | 36.9 (7.5) | 40.4 (10.2) |
| Step test, HR/30 s | 60 (8) | 57 (7) |
| Moderate or vigorous physical activity, h/week | 3.2 (2.1) | 3.7 (3.3) |
None of the means are significantly different between groups at baseline
Mean differences in magnitude of change for key variables between baseline and 16 weeks
| Mean (SD) | Intervention ( | Control ( |
|---|---|---|
| Change in body mass index, kg/m2 | −2.1 (1.3)** | −0.1 (1.5) |
| Change in weight, kg | −5.7 (3.5)** | −0.2 (4.1) |
| Change in waist circumference, cm | −7.1 (6.4)* | −2.5 (7.7) |
| Change in percent body fata | −4.5 (3.8)** | −0.9 (2.3) |
| Change in step test, HR/30 s | −6.0 (8)* | −1.0 (6) |
| Change in physical activity levels, h/week | 2.2 (3.3)* | 0.3 (3.7) |
aOne control and two intervention subjects had missing body composition data (one intervention at baseline; one intervention and one control at 16 weeks)
*P < 0.05; **P < 0.0001
Within group differences for change in cytokine levels between baseline and 16 weeks
| Intervention | Control | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean (SD) |
| Baseline | 16 Weeks |
| Baseline | 16 Weeks | ||
| Variables | Mean (SD) | Mean (SD) |
| Mean (SD) | Mean (SD) |
| ||
| TNFα (pg/mL) | 42 | 5.9 (2.0) | 5.4 (1.9) | 0.03 | 24 | 5.4 (1.3) | 4.6 (1.0) | 0.0001 |
| IL-6 (pg/mL) | 43 | 1.7 (0.9) | 1.4 (0.9) | 0.06 | 24 | 1.7 (1.3) | 1.4 (0.8) | 0.33 |
| IL-8 (pg/mL) | 43 | 4.8 (1.7) | 5.1 (2.0) | 0.29 | 23 | 4.5 (1.5) | 4.4 (1.9) | 0.75 |
| VEGF (pg/mL) | 42 | 29.3 (21.8) | 33.5 (27.0) | 0.20 | 23 | 34.9 (22.5) | 31.3 (16.6) | 0.38 |
IL-6 interleukin-6, IL-8 interleukin-8, TNF-α tumor necrosis factor-α, and VEGF vascular endothelial growth factor
Three sigma outliers (one each for IL-6, IL-8, and VEGF and one for both Il-6 and VEGF in the intervention group; one each for IL-8 and VEGF in the control group) were excluded
Regression model of factors associated with IL-6 levels at 16 weeks in the intervention group (n = 38)
| Variable | β-coefficient | Significance ( |
|
|---|---|---|---|
| Increase in moderate or vigorous physical activity, hours/week | −0.125 | 0.02 | |
| Change in weight, kg | 0.01 | 0.2 | |
| Change in heart rate/min after step test | −0.01 | 0.7 | |
| 0.18 | |||
Excluding one 3-sigma outlier